Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
ID: 357018Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357018

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-079.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic and industrial entities to enhance imaging technologies for cancer-related challenges. This initiative encourages innovative proposals that detail mechanisms for clinical relevance and operational feasibility, with a focus on advancing the development and validation of imaging systems that can improve cancer detection, diagnosis, and treatment. Funding is available for projects with budgets capped at $500,000 per year for up to five years, and applications must involve at least one academic and one industrial investigator. Interested applicants should submit their proposals electronically by January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-079-Full-Announcement.html
    Please provide the text you would like summarized.
    PAR-25-079.html
    The National Cancer Institute (NCI) of the Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) entitled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems." The primary goal of this initiative is to foster collaborations between academic and industrial entities to advance the development and validation of imaging technologies aimed at addressing cancer-related challenges. Emphasizing a translational research focus, this NOFO encourages partnerships that bridge existing collaborations or form new alliances to enhance technological solutions for cancer detection, diagnosis, and treatment. Applications are expected to propose innovative mechanisms and methods, detailing plans for clinical relevance, operational feasibility, and strategic development. Funding is available for projects with budgets capped at $500,000 per year for up to five years. Eligible organizations include higher education institutions, nonprofits, and for-profit organizations, with a specific requirement for all proposals to involve at least one academic and one industrial investigator. Applications must be submitted electronically with strict adherence to the guidelines outlined in the application instructions. The deadlines for applications begin January 5, 2025, with funding decisions based on scientific merit and alignment with program priorities. This NOFO aims to stimulate significant advancements in the field of cancer imaging and patient care.
    Similar Opportunities
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic institutions and industrial organizations to enhance imaging technologies for cancer diagnosis and treatment. This initiative seeks to translate scientific discoveries and engineering advancements into practical tools that address significant challenges in cancer research, focusing on the development and validation of imaging systems that improve detection and treatment monitoring. The grant offers a maximum budget of $500,000 per year for up to five years, with applications required to include at least one academic and one industrial investigator. Interested applicants can find more information and submit their proposals by the deadline of January 7, 2027, by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial entities to develop innovative solutions for critical health challenges, particularly in the fields of cancer and eye health. The program encourages interdisciplinary research teams to enhance and validate technologies that improve diagnostic methods and treatment capabilities, ultimately supporting better health outcomes for diverse populations. The funding amount is capped at $499,000 annually, with a maximum project duration of five years. Initial submissions are due by January 5, 2025, and interested applicants can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems" under the cooperative agreement mechanism (UG3/UH3), aimed at advancing optical imaging technologies to address the challenges of light scattering in biological tissues. This initiative seeks to develop next-generation non-invasive or minimally-invasive optical imaging techniques that enhance penetration depth and resolution, thereby improving diagnostic and research capabilities in biomedical fields. With a total funding commitment of approximately $4.9 million available over a maximum project period of three years, eligible applicants include higher education institutions, non-profits, and small businesses, all of which must submit their proposals electronically through Grants.gov by February 7, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer inflammation through innovative molecular imaging techniques. This initiative encourages applications that leverage in vivo imaging methods to provide deeper insights into the dynamic interactions between inflammation and cancer, moving beyond traditional in vitro approaches. The program seeks multidisciplinary collaborations among cancer biologists and imaging scientists to develop integrated imaging strategies and molecular probes for real-time monitoring of inflammatory responses within the tumor microenvironment. Interested applicants can apply for up to $500,000 annually for a maximum of five years, with the application deadline set for January 8, 2028. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at encouraging revision applications from currently funded NCI P50 specialized centers. This initiative seeks to expand existing research by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program, promoting interdisciplinary collaboration to enhance cancer research effectiveness and validation of these technologies. The funding, estimated at $150,000 per award with a total of three awards available, is intended to support projects that aim to reduce cancer risks, improve screening and diagnostic methods, and advance cancer treatments. Applications are due by 5:00 PM local time on October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)." This initiative aims to support innovative research projects that integrate advanced imaging techniques, biomarkers, and digital pathomics to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic accuracy and reducing overdiagnosis. The program emphasizes the importance of multidisciplinary collaboration in cancer research, particularly focusing on high-risk cancers such as pancreatic and lung cancers. Interested applicants, including higher education institutions, nonprofits, and government entities, must submit their proposals by September 7, 2025, and can find additional information and application details at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance cancer research methodologies, particularly in areas such as diagnostics, treatment, and addressing health disparities. The funding program is part of the National Cancer Institute's (NCI) Innovative Molecular Analysis Technologies (IMAT) Program, with a total estimated funding of $4.3 million available for approximately 10 awards, each capped at $300,000 per year for projects lasting up to three years. Interested applicants must submit their proposals by October 3, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.